ImmuneBiotech AB, the probiotic and microbiome company, is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted a US patent protecting its probiotic product GutMagnific® in the USA. This is an essential asset for ImmuneBiotech to become an emerging key player in the US – the largest market for probiotic dietary supplement.
GutMagnific® is a combination of five probiotic lactobacillus strains, scientifically designed to address the underlying key causes of IBS and is sold as a food supplement www.GutMagnific.com. GutMagnific® is the first product in a new probiotic category ImmuneBiotics™ where products are developed using pharmaceutical precision focused on achieving a healthy balance between the microbiome, the immune system, and the intestinal barrier. The patent US10.632,169B2 covers the composition of matter and use of GutMagnific®.
“I’m extremely pleased to have our first probiotic product GutMagnific® protected by a US patent confirming our outstanding innovation and representing a quality label for ImmuneBiotech. We are of course moving towards the US, the largest probiotic supplement market, with annual sales of USD 2 500 million. GutMagnific® has already gained attention from American consumers, business partners and even medical doctors. We are currently evaluating best strategies to enter the US market including an awarded Catalyst project by Business Sweden having their Chicago office engaged to find best strategies and partners”, said Shahram Lavasani, CEO of ImmuneBiotech.
ImmuneBiotech is an alumni company of SmiLe Incubator, business incubator specialiced in life science, based at Medicon Village in Lund, Sweden.
Or follow this link for a 4 minutes film in English: https://onlineshares.immunebiotics.se/#share?id=0474b153-1ad5-4aa7-b5c1-242559aa2dc6
About GutMagnific® www.GutMagnific.com
GutMagnific® is a super-consortium of five probiotic strains scientifically designed to address the underlying key causes of IBS. It is a patented combination of proprietary lactobacillus strains and is sold as a probiotic food supplement supported by clinical data. GutMagnific® has potential application in several severe and prevalent conditions such as IBS, diarrhea, antibiotic induced diarrhea, Clostridium difficile infection (CDI) and Chronic Fatigue Syndrome (ME/CFS). Is has also the ability to target symptoms such as leaky gut and small intestine bacterial overgrowth (SIBO).
GutMagnific® is currently evaluated in a randomized, double blinded, placebo controlled, 3-arm clinical trial in Myalgic Encephalomyelitis (ME) also called Chronic Fatigue Syndrome (CFS) or post-viral fatigue. The trial is a collaboration with the ME/CFS clinic, Neurological Rehabilitation Clinic, Stora Sköndal, Stockholm, associated with Karolinska Institute, Stockholm, Sweden. As some 70% of ME/CFS patient also suffers from IBS, the hypothesis of the trial is that if the IBS can be ameliorated by GutMagnific® then the ME symptoms could also be improved.
SmiLe Incubator is a life science business incubator based in Medicon Village in Lund. SmiLe helps entrepreneurs to commercialize their ideas. There are currently more than 20 companies in SmiLe, which together with alumni companies, have attracted more than EUR 280 million in venture capital to date since 2014. SmiLe offers business coaching, a large network of contacts and a dynamic community, as well as well-equipped laboratories which is unique of its kind in Sweden. SmiLe is a non-profit organization and receives basic funding from Region Skåne, Lund Municipality, Lund University and Medicon Village. SmiLe´s sponsors are Agilent, Sparbanken Skåne, Awa, Høiberg, Prevas, Setterwalls, Zacco. SmiLe’s listed alumni companies have a market capitalization of almost EUR 750 million (Q4 2019). www.smileincubator.life